White Paper
Evolving regulatory risks, consumer concern and supply chain pressures are all converging on the pharmaceutical industry around PFAS. In this white paper, learn how understanding the exposures, sources, and varying importance of PFAS helps pharmaceutical companies make risk-informed, proactive PFAS reduction and mitigation decisions.
Get the white paper
Managing PFAS in Pharmaceutical Manufacturing
Evolving regulatory risks, consumer concern and supply chain pressures are all converging on the pharmaceutical industry around PFAS. In this white paper, learn how understanding the exposures, sources, and varying importance of PFAS helps pharmaceutical companies make risk-informed, proactive PFAS reduction and mitigation decisions.
Measure Exposure,
Build A Strategy
PFAS are embedded throughout the pharmaceutical lifecycle, in ways both deliberate and unintentional. As global PFAS regulations evolve and supply chain scrutiny grows, pharmaceutical manufacturers need a clear, evidence-based picture of where PFAS originate, why they're there, and where risk can be reduced.
Inside the White Paper
About PFAS and Pharmaceuticals
Learn what PFAS are, why they’re used, why they’re a concern and why they are considered essential in pharmaceutical manufacturing (for now).
4 Pressures for
PFAS Action
See the coninciding pressures making PFAS in pharmaceutical manufacturing a present-tense business issue, regardless of how any single regulatory issue resolves.
Why the Pharmaceutical Challenge is Unique
Understand how the tools and frameworks developed for other PFAS contexts don't always translate directly to pharmaceutical manufacturing.
A Framework for
Addressing PFAS
Explore our experts’ decision-making framework for getting ahead of PFAS risk in pharmaceutical manufacturing – for the short-, mid-, and long-term.